DRC is no stranger to Ebola outbreaks. Why isn’t there a vaccine or treatment to help now?

Key Points:

• The Democratic Republic of Congo is facing its 17th Ebola outbreak, this time caused by the less common Bundibugyo strain, which has limited vaccine and treatment options compared to the more prevalent Zaire strain.
• The existing Ervebo vaccine, approved for the Zaire strain, may offer partial protection against Bundibugyo, but there is insufficient data on its efficacy and safety for this strain, making its use in the current outbreak uncertain.
• New vaccines targeting the Bundibugyo strain are under development, including an experimental recombinant VSV vaccine showing promising results in animal studies, but clinical-grade material and human trials are months away.
• Therapeutic options such as broad-spectrum antiviral drugs and monoclonal antibody cocktails (e.g., MBP134 and Regeneron's Inmazeb) are being prioritized for clinical trials, though logistical challenges exist in administering these treatments in affected regions.
• Despite advancements since the 2014 West Africa Ebola epidemic, funding and preparedness remain inconsistent, with calls for accelerated research and development to better support affected countries, alongside reliance on traditional outbreak control measures like rapid diagnosis, isolation, and community engagement.